Showing results (2291-2300 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|June 19, 2002
Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppressionA-L Hjelm Skog, P Wersäll, P Ragnhammar, et al.Cancer Immunology, Immunotherapy : CII|June 19, 2002
Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancerSupriya Perambakam, Bao-Hua Xue, Jeffrey A Sosman, et al.Cancer Immunology, Immunotherapy : CII|April 17, 2003
Doxorubicin induces specific immune functions and cytokine expression in peritoneal cellsPeter Ujhazy, Gintaras Zaleskis, Enrico Mihich, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2003
Immunocytokines: amplification of anti-cancer immunityCraig B Davis, Stephen D GilliesCancer Immunology, Immunotherapy : CII|April 18, 2003
Human antiglobulin response to foreign antibodies: therapeutic benefit?Gerald L DeNardo, Bonnie M Bradt, Gary R Mirick, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2003
Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigenRathindra Nath Baral, Asim Saha, Sunil K Chatterjee, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2003
Monoclonal antibody drug immunoconjugates for targeted treatment of cancerPamela A Trail, H Dalton King, Gene M DubowchikCancer Immunology, Immunotherapy : CII|June 18, 2003
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancersGovind Ragupathi, Fusataka Koide, Natarajan Sathyan, et al.Cancer Immunology, Immunotherapy : CII|June 27, 2003
Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotypeXueqing Lu, Nikoletta L Kallinteris, Jizhi Li, et al.Cancer Immunology, Immunotherapy : CII|June 27, 2003
Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradicationJoseph LustgartenPageof 652